The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Melnikova A.N.

Russian Medical Academy of Continuous Professional Education

Avxentyeva M.V.

Russian Medical Academy of Continuous Professional Education

Pharmacogenetic testing for personalized statin prescription in Moscow

Authors:

Melnikova A.N., Avxentyeva M.V.

More about the authors

Journal: Medical Technologies. Assessment and Choice. 2024;46(4): 49‑55

DOI: 10.17116/medtech20244604149

Read: 1255 times

Download PDF (RU)
Contact the author
Table of contents

PHARMACOGENETIC TESTING FOR PERSONALIZED STATIN PRESCRIPTION IN MOSCOW
PHARMACOGENETIC TESTING FOR PERSONALIZED STATIN PRESCRIPTION IN MOSCOW

To cite this article:

Melnikova AN, Avxentyeva MV. Pharmacogenetic testing for personalized statin prescription in Moscow. Medical Technologies. Assessment and Choice. 2024;46(4):49‑55. (In Russ.)
https://doi.org/10.17116/medtech20244604149

Подписка 2026 Медицинские технологии. Оценка и выбор (Medical Technologies. Assessment and Choice)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Effect of poly­morphic variants of the HTR2A gene on the effe­ctiveness and safety of sertraline in patients with mixed anxiety-depressive diso­rder. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8):75-84
Recu­rrent coro­nary events as a persistent challenge in cardiology. The role of PCSK9 inhi­bitors in respect of this issue through the example of a local program implemented in St. Pete­rsburg. Russian Journal of Preventive Medi­cine. 2025;(9):78-86
Asso­ciations of poly­morphic variants of CYP2C19*2, *17 with effe­ctiveness and safety of sertraline in adolescents with a depressive episode and suicidal tendencies. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(10-2):12-20
News in mole­cular biology. Digest of scientific publications. Issue 2. Labo­ratory Service. 2025;(4):5-7
Abstract:

OBJECTIVE

To study the features of pharmacogenetic testing for personalized statin prescription in Moscow.

MATERIAL AND METHODS

We analyzed data on medical genetics or pharmacogenetics or availability of equipment necessary for pharmacogenetic testing and personalized statin prescription posted on the websites of 19 hospitals. We clarified the possibility of pharmacogenetic testing through interviewing of laboratory employees by phone and assessed this process according to 6 criteria: biomaterial, molecular genetic methods, analyzed genes and genetic variants, period for completion, availability of consultation after testing and cost. Compliance of studied genes and genetic variants with the Clinical Pharmacogenetics Implementation Consortium (CPIC) recommendations was analyzed. The interviews were conducted twice in June-August 2022 and February—March 2023.

RESULTS

Upon survey, 5 hospitals were conducting pharmacogenetic testing, and 2 hospitals stopped these procedures due to unavailable reagents. Interview results were the same in both periods. There were significant differences in pharmacogenetic testing for most criteria. Period for completion varied from 5 days to 16 weeks, cost — from 4.1 thousand to 139 thousand rubles. The studied genes and genetic variants fully comply with the CPIC recommendations in none hospital.

CONCLUSION

As of February-March 2023, pharmacogenetic testing for personalized statin prescription was performed in several Moscow hospitals, but there were significant differences in testing technologies, timing and cost. The studied genes and genetic variants did not fully comply with the CPIC recommendations that limits testing results for clinical decision-making.

Keywords:

statins
pharmacogenetic testing for personalized statin prescription
pharmacogenetics

Authors:

Melnikova A.N.

Russian Medical Academy of Continuous Professional Education

Avxentyeva M.V.

Russian Medical Academy of Continuous Professional Education

Received:

01.10.2024

Accepted:

15.10.2024

Close metadata

References:

  1. Sindelar RD. Genomics, Other “Omic” Technologies, Personalized Medicine, and Additional Biotechnology-Related Techniques. Pharmaceutical Biotechnology. Fundamentals and Applications. Crommelin DJA, Sindelar RD, Meibohm B, eds. Springer; 2013:179-221.  https://doi.org/10.1007/978-1-4614-6486-0_8
  2. Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. European Heart Journal. 2017;38(32):2459-2472. https://doi.org/10.1093/eurheartj/ehx144
  3. Cholesterol Treatment Trialists’ (CTT) Collaboration; Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670-1681. https://doi.org/10.1016/S0140-6736(10)61350-5
  4. Peyser B, Perry EP, Singh K, Gill RD, Mehan MR, Haga SB, et al. Effects of Delivering SLCO1B1 Pharmacogenetic Information in Randomized Trial and Observational Settings. Circulation Genomic and Precision Medicine. 2018;11(9):e002228. https://doi.org/10.1161/CIRCGEN.118.002228
  5. Vassy JL, Chun S, Advani S, Ludin SA, Smith JG, Alligood EC. Impact of SLCO1B1 Pharmacogenetic Testing on Patient and Healthcare Outcomes: A Systematic Review. Clinical Pharmacology and Therapeutics. 2019;106(2):360-373.  https://doi.org/10.1002/cpt.1223
  6. Brunham LR, Baker S, Mammen A, Mancini GBJ, Rosenson RS. Role of genetics in the prediction of statin-associated muscle symptoms and optimization of statin use and adherence. Cardiovascular Research. 2018;114(8):1073-1081. https://doi.org/10.1093/cvr/cvy119
  7. Brunette CA, Vassy JL. The role of SLCO1B1 genotyping in lowering cardiovascular risk. Pharmacogenomics. 2021;22(11):649-656.  https://doi.org/10.2217/pgs-2021-0075
  8. Miroshnikova VV, Pchelina SN, Donnikov MYu, Vorobyev AS, Tsay VV, Kovalenko LV, et al. The NGS panel for genetic testing in cardiology: from the evaluation of disease risk to pharmacogenetics. Farmakogenetika i farmakogenomika. 2023;(1):7-19. (In Russ.). https://doi.org/10.37489/2588-0527-2023-1-7-19
  9. Sychev DA. Farmakogeneticheskoe testirovanie: klinicheskaya interpretatsiya rezul`tatov. Rekomendatsii dlya praktikuyushhikh vrachej. M., 2011. Accessed September 06, 2024. (In Russ.). https://pharmsuite.ru/download/Pharm/PhG.pdf
  10. Boytsov SA, Drapkina OM, Shlyakhto EV, Konradi AO, Balanova YuA, Zhernakova YuV, et al. Epidemiology of Cardiovascular Diseases and their Risk Factors in Regions of Russian Federation (ESSE-RF) study. Ten years later. Kardiovaskulyarnaya terapiya i profilaktika.. 2021;20(5):3007. (In Russ.). https://doi.org/10.15829/1728-8800-2021-3007
  11. Martsevich SYu, Gaisenok OV, Tripkosh SG, Lukina YuV, Zagrebel’nyy AV. Real practice of statins use and its dependence on follow-up in the specialized medical centre in patients with high cardiovascular risk (according to the PROFILE register). Racional`naya farmakoterapiya v kardiologii. 2013;9(4):362-367. (In Russ.). https://doi.org/10.20996/1819-6446-2013-9-4-362-367
  12. Ezhov MV, Bliznyuk SA, Alekseeva IA, Vygodin VA. Prevalence of hypercholesterolemia and statins intake in the outpatient practice in the Russian Federation (ICEBERG study). Ateroskleroz i dislipidemii. 2017;(4):5-17. (In Russ.).
  13. Silvestrova GA, Fofanova TV, Blankova ZN, Ageyev FT. Opportunities to Increase Low Adherence to Statin Therapy. Effektivnaya farmakoterapiya. 2019;15(20):36-42. (In Russ.). https://doi.org/10.33978/2307-3586-2019-15-20-36-42
  14. Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clinical Pharmacology and Therapeutics. 2022;111(5):1007-1021. https://doi.org/10.1002/cpt.2557
  15. Furberg CD, Pitt B. Withdrawal of cerivastatin from the world market. Current Controlled Trials in Cardiovascular Medicine. 2001;2(5):205-207.  https://doi.org/10.1186/cvm-2-5-205
  16. Akhmetgaleeva AF, Sultanova RI, Akhmetova VL, Zaitseva O.E, Minniakhmetov I.R, Khusainova RI. The use of pharmacogenetic testing for statins in the Republican Medical Genetic Center of the Republic of Bashkortostan. Biomika. 2020;12(4):464-468. (In Russ.). https://doi.org/10.31301/2221-6197.bmcs.2020-39
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.